Brief: Elahere Demonstrates Overall Survival Benefit In The Phase 3 Mirasol Trial In Patients With FRα-Positive Platinum-Resistant Ovarian Cancer

ImmunoGen

03/05/2023 12:29

May 3 (Reuters) - ImmunoGen Inc  IMGN.O :
    * ELAHERE® DEMONSTRATES OVERALL SURVIVAL BENEFIT IN THE
PHASE 3
MIRASOL TRIAL IN PATIENTS WITH FRΑ-POSITIVE PLATINUM-RESISTANT
OVARIAN CANCER
    * IMMUNOGEN INC - SUBMISSION OF MAA IN EUROPE AND SBLA IN US
ANTICIPATED IN H2 2023
    * IMMUNOGEN INC - RESULTS SHOW STATISTICALLY SIGNIFICANT
IMPROVEMENTS IN PFS, ORR, AND OS COMPARED TO CHEMOTHERAPY

Source text for Eikon:  ID:nBw4p859ja 
Further company coverage:  IMGN.O 

 ((Reuters.Brief@thomsonreuters.com;))